Norgine and Jubilant Announce Discovery Collaboration in Gastrointestinal Therapeutic Area
Bangalore, India, & Amsterdam, Netherlands, Oct 18, 2011- Norgine, a leading European specialty pharmaceutical company and Jubilant Biosys Ltd., Bengaluru based subsidiary of Jubilant Life Sciences Ltd, an integrated Pharma & life sciences company of India, announced today, that they have entered into a discovery partnership. The collaboration, spanning an initial period of 3 years will provide a platform for Norgine to develop multiple targets utilizing Jubilant Biosys integrated drug discovery platform targeting gastrointestinal diseases.
Under the terms of the agreement Jubilant shall deliver preclinical candidates to Norgine who will own all rights to further development and commercialization of the candidates. Commenting on the collaboration, Sri Mosur, President and CEO, Global Drug Discovery and Development at Jubilant said: “Jubilant is very pleased to partner with Norgine, a very successful European specialty pharmaceutical company. We are confident our “accelerated discovery” platform will enable Norgine’s quest for novel and optimal therapies in delivering affordable care to the unmet needs of patients in Europe and worldwide in the area of gastrointestinal disease”.
Commenting on the collaboration, Ian Cox, Vice President of Pharmaceutical & Preclinical Development at Norgine said: “We are delighted to be collaborating with Jubilant, a company with a track record in these types of discovery Programmes, and we genuinely look forward to a productive and fruitful relationship”
Norgine is an independent, successful European speciality pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2010, Norgine’s net product sales were €258 million. The Company employs over 1,200 people. Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care. The Company currently markets a range of products in various markets in its key therapeutic areas e.g., MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel cleansing preparation, KLEAN-PREP® for bowel preparation prior to colonoscopy, XIFAXAN® for the treatment of travellers diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer. Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France. For more information: www.norgine.com
Jubilant Discovery Services is New Jersey based US subsidiary of Jubilant Biosys Ltd, a Jubilant Life Sciences Company. It will focus on providing Target Validation and Screening solutions to its global collaborators and more significantly in real time for the US based collaborators. The facility will integrate its activities with R&D facilities of Jubilant in India as well as of its US collaborators to support Lead Generation and Target validation efforts. Staffed with personnel with screening expertise, it will focus in areas of Ion channels, EPhys and screening platforms in GPCR’s and Kinases.
Jubilant Life Sciences Limited is an integrated Pharma and Life Sciences Company. It is the largest Custom Research and Manufacturing Services (CRAMS) player and a leading Drug Discovery and Development Solution (DDDS) provider out of India. The Company provides Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities and a team of ~ 5700 multicultural people across the globe, the Company is committed to deliver value to its customers spread across 70 countries. The Company is well recognized as a ‘Partner of Choice’ by leading life sciences companies worldwide
Disclaimer: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant LifeSciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.